The book

POSITION The Field Guide to Pharmaceutical Positioning

By Mike ReaFrom the author of Deep Positioning

Most pharmaceutical brands don't fail because the science is weak. They fail because no one can say, in one sentence, why a doctor or patient should choose them over what's already on the shelf. In Deep Positioning, Mike Rea showed why that gap exists. In POSITION, he shows exactly how to close it.

  • 8 levers
  • 3 real case studies
  • eBook · Paperback · Hardcover

Why this book

Built on what moves a brand, not on theory.

Market shaping, defined

The deliberate orchestration of supply, demand and stakeholder behaviours to pre-emptively resolve market failures, creating ground where your product doesn't compete; it out-competes.

Drawing on decades spent inside the world's biggest pharmaceutical and biotech companies, Mike Rea distils positioning into a single, repeatable framework: the eight-part POSITION model, built not on theory but on what actually moves a brand from overlooked to indispensable.

Whether you're preparing a launch, rescuing a brand in decline, or just tired of positioning statements nobody outside the building believes, this is the field guide: fewer frameworks you'll forget, more moves you can make on Monday morning.

Deep PositioningDecides what the product is
POSITIONDecides what the market will be when it arrives

You cannot shape the market for a product you have not designed, and you cannot design a product for a market you will not shape.

The POSITION model

Eight levers. One system.

Each lever has a specific job, needs different skills and runs on its own timeline, typically three to five years before filing. Together they turn market friction into your flywheel.

  1. 01

    Prime the Paradigm

    Redefine what counts as success. Shift the baseline so today's standard of care looks inadequate.

    What it costs you

    Evidence, publications, KOL narratives. You are signing up to change how the market thinks about success.

    When it starts

    Phase II, when your endpoint story is forming.

  2. 02

    Orchestrate Opinion Leaders

    Rally KOL networks and advisory boards to co-author publications and symposia, seeding credibility and urgency.

    What it costs you

    Time, relationships, content. KOLs are not purchased; they are partnered with.

    When it starts

    Phase II, as data emerges.

  3. 03

    Shape Stakeholder Narratives

    Translate the same value proposition into three currencies at once: evidence for the physician, return on investment for the payer, empowerment for the patient.

    What it costs you

    Messaging discipline across three audiences at once. One off-message spokesperson undoes the work for all three.

    When it starts

    Phase II/III, as the label takes shape.

  4. 04

    Influence Institutional Guidelines

    Get your endpoint, comparator and patient population into the guidelines and advocacy positions that steer prescribing and coverage.

    What it costs you

    Long-term evidence generation, guideline engagement, health economics. Guidelines move slowly; you must start early.

    When it starts

    Phase III, with outcomes data in hand.

  5. 05

    Target Therapeutic Gaps

    Lay epidemiology and failure-rate data over the category until the unmet need is undeniable, turning a statistic into an imperative a committee can't wave away.

    What it costs you

    Epidemiological and real-world data work that most companies treat as a launch-adjacent nicety, not a lever in its own right.

    When it starts

    Phase II onwards, as the population comes into focus.

  6. 06

    Ignite Innovation Incentives

    Push for the regulatory pathways (breakthrough designations, accepted surrogate endpoints, orphan status) that de-risk your programme and widen who becomes eligible for it.

    What it costs you

    Regulatory strategy and precedent-setting arguments. These pathways are won, not requested.

    When it starts

    Phase II/III, before the pivotal design is locked.

  7. 07

    Optimise Evidence

    Generate the trials, RWE, PROs and health-economic models that every other lever spends as currency.

    What it costs you

    Development budget and trial-design creativity. Evidence is the currency; everything else spends it.

    When it starts

    Phase I onwards. It never stops.

  8. 08

    Nurture Network Effects

    Once belief is moving, build the feedback loops (patient advocacy, prescriber peer networks, payer case studies) that make adoption self-reinforcing instead of something you keep having to buy.

    What it costs you

    Sustained investment after launch. The pay-off compounds, but only if it is still funded past the first year.

    When it starts

    Launch onwards. The lever that keeps paying.

Skip one, and the others stall.

These are not eight separate workstreams. They are one system. The levers work together or they do not work at all.

  • PO

    Prime the Paradigm without Optimise Evidence: you are shouting into a void.

  • OS

    Opinion leaders without stakeholder narratives: voices without a story for two of your three audiences.

  • TI

    Therapeutic gaps without guidelines: the need is proven, but nothing changes in practice.

  • IO

    Innovation incentives without evidence: the pathway opens onto a programme that isn't ready to use it.

  • N…

    Network effects without everything before them: there is nothing left to reinforce.

Case studies

Three cases, read against the method.

A masterclass, a contest still being decided, and a recovery the market forced. Together: what the method would have surfaced, what it would have changed, and what it still might.

Case 01 · The market-shaping masterclass

Lipitor

Lipitor did not just have a great positioning, "Lower is better". It had a market-shaping programme that made that positioning inevitable.

  • $150Blifetime revenue
  • $12.9Bpeak sales, 2006
  • 50%+market share
  • 4Mcardiovascular events averted
  1. Prime the Paradigm

    NCEP targets moved from below 130 mg/dL to below 100 mg/dL. Patients who were "controlled" became "inadequately controlled", and the drug that could get them to the new target was Lipitor.

  2. Opinion leaders and stakeholder narratives

    86,000 primary care physicians reached through symposia. The KOLs were not selling a drug; they were selling a new standard, translated for the physician, the payer and the patient.

  3. Therapeutic gaps and guidelines

    Population data laid over the new target showed exactly how many "controlled" patients now fell short, turning a guideline change into a quantified, urgent gap.

  4. Innovation incentives and evidence

    The FDA accepted LDL as a surrogate endpoint, saving an estimated $300 million and two to three years of development.

  5. Nurture Network Effects

    Physician communities and heart-health advocates folded "lower is better" into their own teaching and campaigns. The paradigm, once shifted, kept shifting on its own.

The drug was well positioned. The market was well shaped.

Case 02 · A contest still being decided

Wegovy / Zepbound

Two molecules, one category, and the most-watched positioning contest in pharma. The lead changed hands while the book was being written.

  • 20.2%weight loss with tirzepatide at 72 weeks, SURMOUNT-5
  • 13.7%with semaglutide in the same head-to-head
  • 20%fewer major CV events for Wegovy in SELECT
  • 17,604people in SELECT, with CVD and no diabetes
Wegovy

The star chosen early

Positioned as "the weight-management drug", not "the obesity injection". SELECT moved the claim from effective weight loss to weight loss that saves lives.

Zepbound

The molecule that took the ground

Competed inside the category Novo built, on the axis a physician sees first: how much weight comes off. Then took obstructive sleep apnoea.

One is a category claim, the other a feature claim, and for now the market prefers the feature. But a feature position is only as durable as the feature, and the next generation of incretins is already in phase III.

Novo chose the position. Lilly chose the molecule.

Case 03 · Better on paper, lost in practice

PCSK9 inhibitors

Repatha and Praluent launched in 2015 with LDL reductions far beyond what statins could achieve, and undersold dramatically. The story most people tell is about price. The positioning story is more interesting.

  • 50–60%LDL reduction at launch
  • $14,000a year, against generic statins
  • 2015launch of Repatha and Praluent
  • Nowrecovering, on the patients who need it
The passive positioning

"The most effective LDL lowerer"

An injection at a price payers would fight, for a number the patient could not feel, in people already on a statin that was working well enough.

The deep positioning

"For the patients statins cannot reach"

Familial hypercholesterolaemia, statin-intolerant and refractory patients, measured against the statins they had already failed.

The recovery is happening now because the market is forcing it: lower prices, outcomes data, and a sharper focus on the patients who need these drugs. It was available at launch.

Efficacy is necessary. Positioning is what makes efficacy sufficient.

Mike Rea

About the author

Mike Rea

35+ years inside pharma's biggest positioning decisions, with direct involvement in more than half of the blockbuster launches of the last 20 years. Founder of IDEA Pharma and creator of the Pharmaceutical Innovation Index.

About Mike

Get the book

Choose your format.

POSITION is available as an eBook, a paperback and a hardcover.

Published by Northern Star Press Ordering for a team? Get in touch